

Vitiligo - Pipeline Insight, 2021

<https://marketpublishers.com/r/V4E82CD53EAEN.html>

Date: May 2021

Pages: 70

Price: US\$ 2,000.00 (Single User License)

ID: V4E82CD53EAEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Vitiligo - Pipeline Insight, 2021," report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Vitiligo pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Vitiligo Understanding

Vitiligo: Overview

Vitiligo is a complex pigment disorder that involves the skin, the hair, and occasionally the mucous membranes. It is a long-term condition where pale white patches develop on the skin. Vitiligo can affect any area of skin, but it commonly happens on the face, neck and hands. Vitiligo is a multifactorial disorder characterized by the loss of functional melanocytes. The diagnosis of vitiligo is primarily made on clinical grounds and is based on history, clinical presentation, and family history (vitiligo, autoimmune disorders). The most extensively characterized clinical markers of active, progressive disease include: Koebner's phenomenon, trichrome lesions, inflammatory lesions and confetti-like depigmentation. The optimal treatment of vitiligo will depend on the subtype of the disease, percent of body surface area (BSA) involved, effect on quality of life, and the perception of the patient concerning the risk to benefit ratio. These treatments

include phototherapy, topical and systemic immunosuppressants, and surgical techniques, stabilizing depigmented lesions and stimulating repigmentation.

'Vitiligo - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vitiligo pipeline landscape is provided which includes the disease overview and Vitiligo treatment guidelines. The assessment part of the report embraces, in depth Vitiligo commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vitiligo collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Vitiligo R&D. The therapies under development are focused on novel approaches to treat/improve Vitiligo.

In September 2020, TAGCyx biotechnologies entered into a research collaboration with CAGE Bio for development of TAGX-0003 for treatment of dermatological autoimmune skin diseases. TAGX-0003 is a DNA aptamer possessing potent IFN- γ antagonistic activity developed by TAGCyx and has already shown effective data in humanized autoimmune skin disease animal model such as alopecia areata when intra-dermally injected.

Vitiligo Emerging Drugs Chapters

This segment of the Vitiligo report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vitiligo Emerging Drugs

Ruxolitinib: Incyte Corporation

Ruxolitinib is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The therapy is currently under Phase III clinical development for the treatment of vitiligo.

PF-06651600: Pfizer

PF-06651600 was developed as an irreversible inhibitor of JAK3 with selectivity over the other three JAK isoforms. A high level of selectivity toward JAK3 is achieved by the covalent interaction of PF-06651600 with a unique cysteine residue (Cys-909) in the catalytic domain of JAK3, which is replaced by a serine residue in the other JAK isoforms. The molecule is currently in Phase II clinical evaluation for the treatment of vitiligo.

Further product details are provided in the report

Vitiligo: Therapeutic Assessment

This segment of the report provides insights about the different Vitiligo drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Vitiligo

There are approx. 22+ key companies which are developing the therapies for Vitiligo. The companies which have their Vitiligo drug candidates in the most advanced stage, i.e. Phase II include, Incyte Corporation.

Phases

DelveInsight's report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vitiligo: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vitiligo therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vitiligo drugs.

Vitiligo Report Insights

- Vitiligo Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Vitiligo Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Vitiligo drugs?

How many Vitiligo drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vitiligo?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vitiligo therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Vitiligo and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Incyte Corporation

Amgen

Boston Pharmaceuticals

Arcutis Biotherapeutics

Pfizer

Dermavant Sciences

Clinuvel Pharmaceuticals

Celgene

TWi Biotechnology

AXIM Biotechnologies

Arrien Pharmaceuticals

Dermira

Key Products

Ruxolitinib

AMG-714

BOS 475

ARQ-252

PF-06651600

Cerdulatinib

Afamelanotide

Apremilast

AC-1101

AX 1602

ARN-4079

QLT-450

Contents

Introduction

Executive Summary

Vitiligo: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Vitiligo – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Vitiligo companies' collaborations, Licensing, Acquisition -Deal Value Trends

Vitiligo Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Ruxolitinib: Incyte Corporation

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

PF-06651600: Pfizer

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)
 Comparative Analysis
AC-1101: TWi Biotechnology
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....
Preclinical/Discovery Stage Products
 Comparative Analysis
QLT-450: Dermira
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
 Comparative Analysis
Vitiligo Key Companies
Vitiligo Key Products
Vitiligo- Unmet Needs
Vitiligo- Market Drivers and Barriers
Vitiligo- Future Perspectives and Conclusion
Vitiligo Analyst Views
Vitiligo Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Vitiligo

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Vitiligo
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Vitiligo - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/V4E82CD53EAEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V4E82CD53EAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970